Bile acid derivative / Chemical chaperone

This page covers all Bile acid derivative / Chemical chaperone drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Endoplasmic reticulum stress pathways; TGR5 receptor (partial), Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1), IRE1α, PERK.

Targets

Endoplasmic reticulum stress pathways; TGR5 receptor (partial) · Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1) · IRE1α, PERK · FXR (farnesoid X receptor) / TGR5 (likely)

Marketed (1)

• Tauroursodeoxycholic Acid · Johns Hopkins University · Neurology / Rare genetic disorders
  Tauroursodeoxycholic acid (TUDCA) is a bile acid that reduces endoplasmic reticulum stress and promotes cell survival by stabilizing mitochondrial function and inhibiting apoptosis pathways.

Phase 3 pipeline (3)

• Doxycycline and tauroursodeoxycholic acid · Fondazione IRCCS Policlinico San Matteo di Pavia · Hepatology / Gastroenterology
  Doxycycline and tauroursodeoxycholic acid combination works by reducing inflammation and oxidative stress while promoting bile acid signaling to protect mitochondrial function and reduce hepatocellular injury.
• Tauroursodeoxycholic Acid Capsules · Beijing Friendship Hospital · Neurology
  Tauroursodeoxycholic acid is a bile acid derivative that modulates the unfolded protein response (UPR) and reduces endoplasmic reticulum stress.
• BDD with UDCA · Ewha Womans University Mokdong Hospital · Hepatology / Gastroenterology
  BDD (a bile acid derivative) combined with UDCA (ursodeoxycholic acid) enhances bile acid signaling and reduces hepatic inflammation and cholestasis.

Patent intelligence

• bile acid derivative patent landscape — aggregated cliff calendar, attackable patents, originator estates